2017

Scalp Psoriasis
Sponsor: Tolmar
A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR
Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to
Reference Listed Drug in the Treatment of Scalp Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Axillary Hyperhidrosis
Sponsor: Brickell Biotech
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and
Efficacy of 5%, 10% and 15% Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects with
Axillary Hyperhidrosis
Phase: 2
Start Date: 2017
End Date: 2017

Psoriasis
Sponsor: Janssen
A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and
Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects With
Moderate to Severe Plaque-type Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Psoriasis
Sponsor: Janssen
A phase 3, Multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO
1959 (Guselkumab) and secukinmab for the treatment of Moderate to Severe Plaque-Type Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Atopic Dermatitis
Sponsor: Incyte
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1 % Cream-Controlled
Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults
With Atopic Dermatitis
Phase: 2
Start Date: 2017
End Date: 2018

Psoriasis
Sponsor: Ferndale
A Multicenter study of psorx lotion in subjects with moderate plaque psoriasis
Phase:
Start Date: 2017
End Date: 2018

Cutaneous Common Warts
Sponsor: Cutanea
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and
Safety of CLS006 versus Vehicle in Subjects 12 years of age or older with Cutaneous Common Warts
12 years or older
Phase: 3
Start Date: 2017
End Date: 2018

Common Warts
Sponsor: Aclaris
A Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied
Once A Week In Subjects With Common Warts
Phase: 2
Start Date: 2017
End Date: 2018

Severe Acne Vulgaris
Sponsor: Foamix
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical
Administration of FMX101 for 12 weeks in the Treatment of Moderate – to – Severe Acne Vulgaris
Phase: 3
Start Date: 2017
End Date: 2018

Moderate to Severe Atopic Dermatitis
Sponsor: Regeneron
A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of
Dupilumab Monotherapy In Patients ≥12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis
12 To 18 Years Of Age
Phase: 3
Start Date: 2017
End Date: 2018

Facial Acne Vulgaris
Sponsor: Therapeutics
A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Phase: 2
Start Date: 2017
End Date: 2018

Pruritus
Sponsor: Sienna
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with
Psoriasis Vulgaris
Phase: 2b
Start Date: 2017
End Date: 2018

Facial Papulopustular Rosacea
Sponsor: Foamix
A Randomized, Multicenter, Double-blind, Vehicle controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular
Rosacea (FX2016-11)
Phase:
Start Date: 2017
End Date: 2018

Plaque Psoriasis
Sponsor:
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Phase:
Start Date: 2017
End Date: 2018